Exact Mass: 649.2424030000001

Exact Mass Matches: 649.2424030000001

Found 56 metabolites which its exact mass value is equals to given mass value 649.2424030000001, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Dihydro,di-Ac-Ravidomycin

Dihydro,di-Ac-Ravidomycin

C35H39NO11 (649.2522984)


   

Thr Cys Tyr Thr Tyr

Thr Cys Tyr Thr Tyr

C29H39N5O10S (649.2417514)


   

Ala Glu Phe His Phe

Ala Glu Phe His Phe

C32H39N7O8 (649.2859974)


   

Cys Arg Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O5S (649.2794723999999)


   

Cys Trp Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O5S (649.2794723999999)


   

Cys Trp Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C31H39N9O5S (649.2794723999999)


   

Met Gln Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C32H39N7O6S (649.2682394000001)


   

Met Trp Gln Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanoic acid

C32H39N7O6S (649.2682394000001)


   

Met Trp Trp Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanoic acid

C32H39N7O6S (649.2682394000001)


   

Gln Met Trp Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C32H39N7O6S (649.2682394000001)


   

Gln Trp Met Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanoic acid

C32H39N7O6S (649.2682394000001)


   

Gln Trp Trp Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanoic acid

C32H39N7O6S (649.2682394000001)


   

Arg Cys Trp Trp

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O5S (649.2794723999999)


   

Arg Trp Cys Trp

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O5S (649.2794723999999)


   

Arg Trp Trp Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanoic acid

C31H39N9O5S (649.2794723999999)


   

Raloxifene 6-glucuronide

Raloxifene-6-glucuronide

C34H35NO10S (649.198157)


   

Raloxifene-4-glucuronide

Raloxifene-4-glucuronide

C34H35NO10S (649.198157)


   

Trp Cys Arg Trp

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O5S (649.2794723999999)


   

Trp Cys Trp Arg

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C31H39N9O5S (649.2794723999999)


   

Trp Met Gln Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanoic acid

C32H39N7O6S (649.2682394000001)


   

Trp Met Trp Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanoic acid

C32H39N7O6S (649.2682394000001)


   

Trp Gln Met Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanoic acid

C32H39N7O6S (649.2682394000001)


   

Trp Gln Trp Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanoic acid

C32H39N7O6S (649.2682394000001)


   

Trp Arg Cys Trp

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C31H39N9O5S (649.2794723999999)


   

Trp Arg Trp Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanoic acid

C31H39N9O5S (649.2794723999999)


   

Trp Trp Cys Arg

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-5-carbamimidamidopentanoic acid

C31H39N9O5S (649.2794723999999)


   

Trp Trp Met Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanoic acid

C32H39N7O6S (649.2682394000001)


   

Trp Trp Gln Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanoic acid

C32H39N7O6S (649.2682394000001)


   

Trp Trp Arg Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-sulfanylpropanoic acid

C31H39N9O5S (649.2794723999999)


   

AEFHF

Ala-Glu-Phe-His-Phe

C32H39N7O8 (649.2859974)


   

TCYTY

Thr Cys Tyr Thr Tyr

C29H39N5O10S (649.2417514)


   

Nintedanib Esylate

Nintedanib Ethanesulfonate Salt

C33H39N5O7S (649.2570064)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents

   

UNII:73033I28Y6

Mosapride citrate dihydrate

C27H37ClFN3O12 (649.2049684000001)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D005765 - Gastrointestinal Agents

   

N4-benzoyl-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2-O-[(methylthio)methyl]cytidine

N4-benzoyl-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2-O-[(methylthio)methyl]cytidine

C30H47N3O7SSi2 (649.2673112)


   

Fmoc-His(MMt)-OH

Fmoc-His(MMt)-OH

C41H35N3O5 (649.257658)


   

5-DMT-Bz-rC

5-DMT-Bz-rC

C37H35N3O8 (649.2424030000001)


5'-O-DMT-Bz-Rc is a modified nucleoside and can be used to synthesize DNA or RNA.

   

bis(trimethylsilyl)azanide,thulium(3+)

bis(trimethylsilyl)azanide,thulium(3+)

C18H54N3Si6Tm (649.2275434)


   

Sibofimloc

Antibiotic-202

C35H39NO11 (649.2522984)


C254 - Anti-Infective Agent > C258 - Antibiotic

   

N-[(S)-2-Amino[1,1-binaphthalen]-2-yl]-N-[(9R)-6-methoxycinchonan-9-yl]thiourea

N-[(S)-2-Amino[1,1-binaphthalen]-2-yl]-N-[(9R)-6-methoxycinchonan-9-yl]thiourea

C41H39N5OS (649.2875164)


   

Glycine, N-[2-[[(9H-fluoren-9-ylMethoxy)carbonyl]aMino]ethyl]-N-[[6-[[(phenylMethoxy)carbonyl]aMino]-9H-purin-9-yl]acetyl]-

Glycine, N-[2-[[(9H-fluoren-9-ylMethoxy)carbonyl]aMino]ethyl]-N-[[6-[[(phenylMethoxy)carbonyl]aMino]-9H-purin-9-yl]acetyl]-

C34H31N7O7 (649.2284855999999)


   

1,6-anhydrous-N-Acetylmuramyl-tripeptide

1,6-anhydrous-N-Acetylmuramyl-tripeptide

C26H43N5O14 (649.2806378)


   

Gc2-3Lac

Gc2-3Lac

C23H39NO20 (649.2065334)


   

alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-beta-D-Glcp

alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-beta-D-Glcp

C23H39NO20 (649.2065334)


alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-D-Glcp in which the anomeric configuration of the reducing-end glucose is beta.

   

limonin 17-beta-D-glucoside(1-)

limonin 17-beta-D-glucoside(1-)

C32H41O14- (649.2496186000001)


   

alpha-Neu5Gc-(2->6)-beta-Gal-(1->4)-Glc

alpha-Neu5Gc-(2->6)-beta-Gal-(1->4)-Glc

C23H39NO20 (649.2065334)


   

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-methoxybenzenesulfonamide

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-methoxybenzenesulfonamide

C32H38F3N3O6S (649.2433284000001)


   

NeuGc(a2-3)[Gal(b1-4)]Gal

NeuGc(a2-3)[Gal(b1-4)]Gal

C23H39NO20 (649.2065334)


   

3,5-dideoxy-5-glycolamido-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranosyl-(1->4)-D-gluco-hexopyranose

3,5-dideoxy-5-glycolamido-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranosyl-(1->4)-D-gluco-hexopyranose

C23H39NO20 (649.2065334)


   

NeuGc(a2-6)Gal(b1-4)b-Glc

NeuGc(a2-6)Gal(b1-4)b-Glc

C23H39NO20 (649.2065334)


   

NeuGc(a2-3)[Gal(b1-4)]a-Gal

NeuGc(a2-3)[Gal(b1-4)]a-Gal

C23H39NO20 (649.2065334)


   

NeuGc(a2-3)[Gal(b1-4)]b-Gal

NeuGc(a2-3)[Gal(b1-4)]b-Gal

C23H39NO20 (649.2065334)


   

alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-D-Glcp

alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-D-Glcp

C23H39NO20 (649.2065334)


An amino trisaccharide consisting of an N-glycoloylneuraminosyl residue linked alpha(2->3) to a lactose moiety.

   

Mosapride citrate hydrate

Mosapride citrate hydrate

C21H25ClFN3O3. C6H8O7. 2H2O (649.2049684000001)


   

PS 16:1/7:3;O3

PS 16:1/7:3;O3

C29H48NO13P (649.2863127999999)


   

PS 23:4;O3

PS 23:4;O3

C29H48NO13P (649.2863127999999)


   

ST 24:6;O8;HexNAc

ST 24:6;O8;HexNAc

C32H43NO13 (649.2734268)